Subject(s)
Histiocytosis, Non-Langerhans-Cell/pathology , Immunosuppressive Agents/therapeutic use , Joint Diseases/pathology , Wound Healing/physiology , Drug Therapy, Combination , Etanercept , Finger Joint/diagnostic imaging , Finger Joint/drug effects , Finger Joint/pathology , Histiocytosis, Non-Langerhans-Cell/diagnostic imaging , Histiocytosis, Non-Langerhans-Cell/drug therapy , Humans , Immunoglobulin G/therapeutic use , Isoxazoles/therapeutic use , Joint Diseases/diagnostic imaging , Joint Diseases/drug therapy , Leflunomide , Male , Middle Aged , Prednisone/therapeutic use , Radiography , Receptors, Tumor Necrosis Factor/therapeutic use , Remission Induction , Wound Healing/drug effectsABSTRACT
OBJECTIVE: To describe the clinical features and outcomes of patients with localized vasculitis of the gastrointestinal tract (LVGT). METHODS: Medical records of 608 patients diagnosed with vasculitis involving the intra-abdominal vasculature and/or abdominal viscera between January 1996 and December 2007 were reviewed. Only patients with histopathological confirmation or typical angiographic findings of vasculitis localized to the abdomen were included. RESULTS: We identified 18 cases with LVGT over the 12-year study period. The patients were predominantly Caucasian (89%) and female (67%) with a median age at diagnosis of 53.5 (range 17.4-83.3) years. Most of the patients presented with abdominal pain and 12 (66.6%) patients presented with an acute abdomen requiring surgical intervention. At diagnosis, the median ESR was 30.5 (range 4-77) mm/h. Autoantibody screening was generally unrevealing. Abdominal CT scan findings included: bowel wall thickening, bowel infarction and solid organ infarcts. In 14 patients, the diagnosis of vasculitis was established by abdominal angiography. Histological evidence of vasculitis was recorded in 5 (28%) patients, most commonly from gall bladder or small intestine specimens. Corticosteroid therapy was administered to 10 (56%) patients, 5 of whom also received other immunosuppressive agents. Median duration of follow-up was 10.5 (range 2-156) months. No evidence of vasculitis outside the abdomen was observed during follow-up. Seven (39%) patients died during the follow-up period. Survival of the patient cohort (compared with an age-matched US white population) was significantly reduced (P < 0.001). CONCLUSION: LVGT is an uncommon form of vasculitis that can be associated with significant morbidity and mortality.